BC Week In Review | Oct 26, 2018
Clinical News

Vertex discontinues development of spinal cord injury compound VX-210

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) discontinued development of acute spinal cord injury candidate VX-210 after a DSMB recommended stopping a Phase IIb trial for futility following an interim analysis. Vertex has rights to VX-210 from BioAxone...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Innovations | May 21, 2009
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Reticulon 4 receptor (RTN4R; NgR) Studies in mice suggest that a soluble peptide fragment of NgR (sNgR)...
BC Week In Review | May 11, 2009
Company News

Alseres, BioAxone deal

Alseres (formerly Boston Life Sciences Inc. ) is no longer required to pay milestones to BioAxone under a 2006 deal that granted Alseres exclusive, worldwide rights to BioAxone's Cethrin . In return, Alseres has an undisclosed time...
BC Innovations | May 7, 2009
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Integrin a9 (ITGA9) Studies in cell culture and in rats suggest that upregulating ITGA9 could help treat...
BC Innovations | Oct 9, 2008
Targets & Mechanisms

In the mood for regeneration

Researchers at the University of Texas Southwestern Medical Center have found that lithium, the marketed mood stabilizer, might have utility in spinal cord injury, an indication for which there are no approved drugs. 1 In...
BC Week In Review | Sep 22, 2008
Clinical News

Cethrin regulatory update

The EC granted Orphan Drug designation for Cethrin to treat traumatic spinal cord injury (SCI). The recombinant C3 exoenzyme protein, a Rho GTPase antagonist, mixed with a fibrin sealant also has Orphan designation in the...
BC Week In Review | Aug 18, 2008
Clinical News

Cethrin: Phase IIb start

In 1Q09, Alseres will begin a double-blind, placebo-controlled, North American Phase llb trial (ALSE-C-01) in about 50 patients. The study was initially slated to begin in 1H08. The company has an exclusive worldwide license to...
BC Week In Review | May 19, 2008
Clinical News

Cethrin: Phase I/IIa data

Twelve-month data from an open-label, North American Phase I/lla trial showed that 5 of 13 (38%) patients with cervical injury had a 2-grade or better improvement in the American Spinal Injury Association (ASIA) Impairment Scale...
BC Week In Review | May 12, 2008
Company News

Alseres, BioAxone deal

Alseres (formerly Boston Life Sciences Inc. ) received an option to pay a fee in return for reducing the amount of potential milestones and royalties due to BioAxone under a 2007 deal to develop BioAxone’s Cethrin...
Items per page:
1 - 10 of 19